UCK-13921-20699
3 vaccinations
2 coded responses
23 check-ins
2 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 31-35
- ZIP prefix
- 606 / IL
- Registered
- 2020-12-16
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Registered dependents
GAF-31562-76759
Child or adolescent in my care · Female · 2022-06-25
Timeline
-
2020-12-16
Registered in v-safe
-
2020-12-26
Dose 1 — Pfizer-BioNTech
- 2020-12-26
- 2020-12-27
- 2020-12-28
- 2020-12-29
- 2020-12-30
- 2020-12-31
- 2021-01-01
- 2021-01-02
- 2021-01-09
-
2021-01-14
Dose 2 — Pfizer-BioNTech
- 2021-01-14
-
2021-01-15
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Headache, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
-
2021-01-15
Report sent to call center — days 1–6 daily, dose 2Be unable to do your normal daily activities1 call case(s)
- 2021-01-16
-
2021-01-17
Survey response — days 1–6 daily, dose 2MedDRA: Night sweats — Feeling: Good · HeadacheFree text: Night sweatsMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-01-18
- 2021-01-20
- 2021-01-21
- 2021-01-28
- 2021-02-04
- 2021-02-11
- 2021-02-18
- 2021-02-25
- 2021-04-15
-
2021-10-03
Dose 3 — Pfizer-BioNTech
-
2022-01-14
Survey response — 12 months, dose 2MedDRA: Antinuclear antibody positive, Habitual abortion — Feeling: Good · Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Recurrent pregnancy loss and positive ANA 1:640 (tested negative for lupus)MedDRA releases: 2024-11 · check-in free text available
-
2022-01-14
Report sent to call center — 12 months, dose 2Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
-
2022-01-17
Call successfulParticipant prefers to complete VAERS report online
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2020-12-26 | Pfizer-BioNTech | |
| 2 | 2021-01-14 | Pfizer-BioNTech | |
| 3 | 2021-10-03 | Pfizer-BioNTech | No |
Call center
2 call center cases
1 successful · 1 priority 2/3 (triaged and no follow up)
Free text
Release 2 — days 1–6 daily, dose 2
Systemic reaction (other): Night sweats
Release 10 — 12 months, dose 2
Symptoms: Recurrent pregnancy loss and positive ANA 1:640 (tested negative for lupus)
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Antinuclear antibody positive | · | · | ✓ |
| SD | Habitual abortion | · | · | ✓ |
| SRO | Night sweats | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release